Cancer Treatment Reviews
Volume 27, Issue 4 , Pages 201-209 , August 2001

Gender and survival in malignant tumours

  • R. Molife

      Affiliations

    • Department of Cellular Pathology and Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, UK
    • ,
  • P. Lorigan

      Affiliations

    • Department of Cellular Pathology and Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, UK
    • ,
  • S. MacNeil

      Affiliations

    • Department of Medicine Clinical Sciences Centre, Northern General Hospital, Sheffield, UK

References 

    REFERENCES
  1. Miller JG, MacNeil S. Gender and cutaneous melanoma. Brit J Derm. 1997;136:657–665
  2. Dewhurst LO, Gee JW, Rennie IG. Tamoxifen, 17b estradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. Br J Canc. 1997;75:860–868
  3. Richardson B, Price A, Wagner M. Investigation of female survival benefit in metastatic melanoma. Br J Canc. 1999;;80:2025–2033
  4. Ramantanis G, Besbeas S, Garas JG. Breast cancer in the male: a report of 138 cases. World J Surg. 1980;4:621–624
  5. Erlichman C, Murphy KC, Elhakim T. Male breast cancer: a 13 year review of 89 patients. J Clin Oncol. 1984;2:903–909
  6. Guinee VF, Olsson H, Moller T. The prognosis of breast cancer in males. Cancer. 1993;71:154–161
  7. Fisher B, Slack N, Katrych D. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet. 1975;140:528–534
  8. Borgen PI, Senie RT, McKinnon MP. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol. 1997;4:385–388
  9. Rudan I, Rudan N, Basic N. Differences between male and female breast cancer-III prognostic features. Acta Med Croatica. 1997;51:135–141
  10. Heller KS, Rosen PP, Schottenfeld D. In:  Surg Ann editors. Male breast cancer: A clinicopathological study of 97 cases. 1978;p. 60–65
  11. Bouchardy C, Fioretta G, De Perrot M. Determinants of long term survival after surgery for cancer of the lung – a population-based study. Cancer. 1999;86:2229–2237
  12. Engeland A, Bjorge T, Haldorsen T. Prognosis of patients with lung cancer diagnosed in Norway, 1954–93. Canc Causes Cont. 1998;9:57–65
  13. Beattie CW, Hansen NW, Thomas PA. Steroid receptors in human lung cancer. J Surg Oncol. 1985;45:4206–4214
  14. Lee YT. Better prognosis of many cancers in female: a phenomenon not explained by study of steroid receptors. J Surg Oncol. 1984;25:255–262
  15. Fotsis T, Zhang Y, Pepper MS. The endogenous oestrogen metabolite 2-methoxyostradiol inhibits angiogenesis and suppresses tumour growth. Nature. 1994;368:237–239
  16. Hilsenbeck SG, Raub WA, Sridhar KS. Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol. 1993;16(4):301–309
  17. Sridhar KS, Raub WA, Duncan RC. Lung carcinoma in 1336 patients. Am J Clin Oncol. 1991;14(6):496–508
  18. Johnson BE, Steinberg SM, Phelps R. Female patients with small cell lung cancer live longer than male patients. Am J Med. 1988;85:194–196
  19. Godwin JD, Brown CC. Some prognostic factors in survival of patients with cancer of the colon and rectum. J Chron Dis. 1975;28:441–454
  20. Wolters U, Stutzer H, Isenberg J. Gender related survival in colorectal cancer. Anticancer Res. 1996;16(3A):1281–1289
  21. McDermott FT, Hughes ESR, Pihl E. Comparative results of surgical management of single carcinomas of the colon and rectum: a series of 1939 patients managed by one surgeon. Br J Surg. 1981;68:850–855
  22. Jolly KD, Scott JP, Mckinnon MJ. Diagnosis and survival in carcinoma of the large bowel. Aust N Z J Surg. 1982;52:12–16
  23. McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. JNCI. 1980;65:1201–1207
  24. Wiggers T, Arends JW, Volovics A. Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Col Rect. 1987;51:33–41
  25. Bollschweilwer E, Boettcher K, Hoelscher AH. Is the prognosis for Japanese and German patients with gastric cancer really different?. Cancer. 1993;7:2918–2925
  26. Arak A, Kull K. Factors influencing survival of patients after radical surgery for gastric cancer. Acta Oncol. 1994;33(8):913–920
  27. Maguire A, Porta M, Sanz-Anquela JM. Sex as a prognostic factor in gastric cancer. Eur J Canc. 1996;32A(8):1303–1309
  28. Bako G, Ferenczi L, Hanson J. Factors influencing the survival of patients with cancer of the stomach. Clin Invest Med. 1985;8(1):22–28
  29. Baylor SM, Berg JW. Cross-classification and survival characteristics of 5,000 cases of cancer of the pancreas. J Surg Oncol. 1973;335–358
  30. Kalser MH, Barkin J, MacIntyre JM. Pancreatic cancer – assessment of prognosis by clinical presentation. Cancer. 1985;56:397–402
  31. Sugimachi K, Matsuoka H, Matsufuji H. Survival rates of women with carcinoma of the oesophagus exceed those of men. Surg Obs and Gyn. 1987;164:541–544
  32. Badwe RA, Patil PK, Bhnasali MS. Impact of age and sex on survival after curative resection for carcinoma of the oesophagus. Cancer. 1994;74:2425–2429
  33. Cederqvist C, Nielsen J, Berthelsen A. Cancer of the oesophagus – I. 1002 cases, survey and survival. Acta Chir Scand. 1978;144:227–231
  34. Van Andel JG, Dees J, Dijkhus CM. Carcinoma of the oesophagus. Ann Surg. 1979;190:684–689
  35. Rooser B, Attewell R, Berg NO. Survival in soft tissue sarcoma: prognostic variables identified by multivariate analysis. Acta Orthop Scand. 1987;58:516–522
  36. El-Jabbour JN, Akhtar SS, Kerr GR. Prognostic factors for survival in soft tissue sarcoma. Br J Canc. 1990;62:857–861
  37. Baldursson G, Agnarsson BA, Benediktsdottir KR. Soft tissue sarcomas in Iceland 1955Ð1988 Ð analysis of survival and prognostic factors. Acta Oncol. 1991;30(5):563–568
  38. Coindre JM, Terrier P, Bunh Bui N. Prognostic factors in adult patients with locally controlled soft tissue sarcoma: a study of 546 patients from the French Federation of Cancer Centres Sarcoma Group. J Clin Oncol. 1996;14(3):869–877
  39. Van Glabbeke M, Van Oosterom AT, Oosterhur JW. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185v patients treated with anthra-cycline containing first-line regimens – a European Organisation for the Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Onc. 1999;17(1):150–157
  40. Newaishy GA, Kelly CG. An audit of survival in small cell lung cancer. Clin Oncol. 1992;4:362–367
  41. Palomares MR, Sayre JW, Shekar KC. Gender influence on weight-loss pattern and survival of non-small cell lung carcinoma patients. Cancer. 1996;78:2119–2126
  42. Maurer LH, Pajak TF. Prognostic factors in small cell carcinoma of the lung: a Cancer and Leukaemia Group B Study. Cancer Treat Rep. 1981;65:767–774
  43. Rossing TH, Rossing RG. Survival in lung cancer – an analysis of the effects of age, sex, resectability and histopathologic type. Am Rev Respir Dis. 1982;126:771–777
  44. Paesmans M, Sculier JP, Libert P. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1 052 patients. J Clin Oncol. 1995;13:1221–1230

PII: S0305-7372(01)90220-8

doi: 10.1053/ctrv.2001.0220

Cancer Treatment Reviews
Volume 27, Issue 4 , Pages 201-209 , August 2001

Article Tools